organization · Reporting owner

GV 2019, L.P.

Disclosed activity across 5 companies

Tapewire entity: 10526
SEC CIK: 0001845041

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Prime Medicine, Inc.PRME · Entity 5281	10% owner	June 20, 2023	June 22, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Prime Medicine, Inc.

Report date June 20, 2023 · Filed June 22, 2023

Jointly reported with GV 2019 GP, L.L.C., GV 2019 GP, L.P., GV 2021 GP, L.L.C., GV 2021 GP, L.P., GV 2021, L.P., Alphabet Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy GV 2019, L.P.	10,100,058	Last balance in matching sequence After 2023-06-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2023-06-20 · Other · Disposed 37,405 · Balance 10,119,061 F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 3 · 2023-06-21 · Other · Disposed 19,003 · Balance 10,100,058 F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Alphabet Holdings LLC	0	Reported balance After 2023-06-20 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2023-06-20 · Sale · Disposed 37,405 · Balance 0 F3: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.90 to $15.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy Alphabet Holdings LLC	0	Reported balance After 2023-06-21 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2023-06-21 · Sale · Disposed 19,003 · Balance 0 F3: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.78 to $15.09, inclusive. F5: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy GV 2021, L.P.	1,762,440	Reported balance Holding disclosure · report date 2023-06-20 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 1,762,440 F7: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). The general partner of the 2021 Partnership is GV 2021 GP, L.P. (the "2021 GP"). The general partner of the 2021 GP is GV 2021 GP, L.L.C. ("GV 2021 LLC"). The sole member of GV 2021 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) the securities directly beneficially owned by the 2021 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023.

F2: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F3: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.90 to $15.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4.

F5: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.78 to $15.09, inclusive.

F7: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). The general partner of the 2021 Partnership is GV 2021 GP, L.P. (the "2021 GP"). The general partner of the 2021 GP is GV 2021 GP, L.L.C. ("GV 2021 LLC"). The sole member of GV 2021 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) the securities directly beneficially owned by the 2021 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Decibel Therapeutics, Inc.

Report date February 17, 2021 · Filed February 17, 2021

Jointly reported with GV 2019 GP, L.L.C., GV 2019 GP, L.P.

Section 16 reporting ended · disclosed 2021-02-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy GV 2019, L.P.	819,631	Reported balance After 2021-02-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-02-17 · Conversion · Acquired 819,631 · Balance 819,631 F1: The Series D Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 5.3:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series D Preferred Stock had no expiration date. F2: The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2019 GP, L.P., GV 2019 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectBy GV 2019, L.P.	0	Reported balance After 2021-02-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-02-17 · Conversion · Disposed 4,344,048 · Balance 0 F1: The Series D Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 5.3:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series D Preferred Stock had no expiration date. F2: The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2019 GP, L.P., GV 2019 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series D Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 5.3:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series D Preferred Stock had no expiration date.

F2: The reported securities are held directly by GV 2019, L.P. GV 2019 GP, L.P. (the general partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the general partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the sole member of GV 2019 GP, L.L.C.), XXVI Holdings Inc. (the sole member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have sole power to vote or dispose of these shares. Each of GV 2019 GP, L.P., GV 2019 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. disclaim beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Ethos Technologies Inc.

Report date July 27, 2026 · Filed July 29, 2026

Jointly reported with GV 2019 GP, L.L.C., GV 2019 GP, L.P., GV 2021 GP, L.L.C., GV 2021 GP, L.P., GV 2021, L.P., Alphabet Inc.

Section 16 reporting ended · disclosed 2026-07-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectBy GV 2019, L.P.	2,443,425	Last balance in matching sequence After 2026-07-28 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2026-07-27 · Other · Disposed 196,931 · Balance 2,561,563 F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the GV 2019, L.P. ("2019 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2: The securities reported in this row are directly beneficially owned by the 2019 Partnership. GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Row 3 · 2026-07-28 · Other · Disposed 118,138 · Balance 2,443,425 F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the GV 2019, L.P. ("2019 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2: The securities reported in this row are directly beneficially owned by the 2019 Partnership. GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy Alphabet Holdings LLC	0	Reported balance After 2026-07-27 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2026-07-27 · Sale · Disposed 196,931 · Balance 0 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.21 to $19.795, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4. F4: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Exchange Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy Alphabet Holdings LLC	0	Reported balance After 2026-07-28 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2026-07-28 · Sale · Disposed 118,138 · Balance 0 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.45 to $19.19, inclusive. F4: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Exchange Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Class A Common StockSEC Table I · non-derivative	IndirectBy GV 2021, L.P.	571,907	Reported balance Holding disclosure · report date 2026-07-27 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 571,907 F6: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the GV 2019, L.P. ("2019 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2: The securities reported in this row are directly beneficially owned by the 2019 Partnership. GV 2019 GP, L.P. (the "2019 GP") is the general partner of the 2019 Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the 2019 GP. Alphabet Holdings is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2019 Partnership. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.21 to $19.795, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4.

F4: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Exchange Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.45 to $19.19, inclusive.

F6: The securities reported in this row are directly beneficially owned by GV 2021, L.P. (the "2021 Partnership"). GV 2021 GP, L.P. (the "2021 GP") is the general partner of the 2021 Partnership. GV 2021 GP, L.L.C. ("GV 2021 LLC") is the general partner of the 2021 GP. Alphabet Holdings is the sole member of GV 2021 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the securities directly beneficially owned by the 2021 Partnership. Each of the 2021 GP, GV 2021 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

IonQ, Inc.

Report date April 11, 2022 · Filed April 12, 2022

Jointly reported with GV 2019 GP, L.L.C., GV 2019 GP, L.P., Alphabet Inc.

Section 16 reporting ended · disclosed 2022-04-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy GV 2019 L.P.	4,556,532	Reported balance Holding disclosure · report date 2022-04-11 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 4,556,532 F1: The reported securities are held directly by GV 2019, L.P. (the "Partnership"). GV 2019 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the sole controlling stockholder of XXVI. Each of the GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities are held directly by GV 2019, L.P. (the "Partnership"). GV 2019 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2019 GP, L.L.C. ("GV 2019 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2019 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the sole controlling stockholder of XXVI. Each of the GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Verve Therapeutics, Inc.

Report date July 25, 2025 · Filed July 28, 2025

Jointly reported with GV 2017 GP, L.L.C., GV 2017 GP, L.P., GV 2017, L.P., GV 2019 GP, L.L.C., GV 2019 GP, L.P., GV 2023 GP, L.L.C., GV 2023 GP, L.P., GV 2023, L.P., Alphabet Inc.

Section 16 reporting ended · disclosed 2025-07-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy GV 2017 L.P.	Reported balance After 2025-07-25 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2025-07-25 · Other · Disposed 6,108,442 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F3: The securities reported in this row are directly held by GV 2017, L.P. (the "2017 Partnership"). The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy GV 2019 L.P.	Reported balance After 2025-07-25 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2025-07-25 · Other · Disposed 4,260,047 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F4: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy GV 2023, L.P.	Reported balance After 2025-07-25 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2025-07-25 · Other · Disposed 1,800,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business, F2: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent. F5: The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the "2023 Partnership"). GV 2023 GP, L.P. (the "2023 GP") is the general partner of the 2023 Partnership. GV 2023 GP, L.L.C. ("GV 2023 LLC") is the general partner of the 2023 GP. Alphabet Holdings is the sole member of GV 2023 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2023 Partnership. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock (the "Common Stock"). In exchange for each share, tendering stockholders received: (i) $10.50 per share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR" and, together with the Cash Consideration, the "Offer Price"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business,

F2: (continued from footnote 1) in accordance with the terms and subject to the conditions and other provisions of a contingent value rights agreement entered into by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and an indirect wholly owned subsidiary of Parent.

F3: The securities reported in this row are directly held by GV 2017, L.P. (the "2017 Partnership"). The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole member of GV 2017 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F4: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F5: The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the "2023 Partnership"). GV 2023 GP, L.P. (the "2023 GP") is the general partner of the 2023 Partnership. GV 2023 GP, L.L.C. ("GV 2023 LLC") is the general partner of the 2023 GP. Alphabet Holdings is the sole member of GV 2023 LLC. XXVI is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2023 Partnership. Each of the 2023 GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 12, 2023 Filed Jun 13, 2023 20:20 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	16,031	$14.98	$240,150.79	Disclosure SEC source: 0001209191-23-036666 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.38, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 12, 2023 Filed Jun 13, 2023 20:20 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	16,031	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036666 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,286,717 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 09, 2023 Filed Jun 13, 2023 20:20 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	15,672	$14.48	$226,983.84	Disclosure SEC source: 0001209191-23-036666 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.925, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 09, 2023 Filed Jun 13, 2023 20:20 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	15,672	$0.00	$0.00	Disclosure SEC source: 0001209191-23-036666 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,302,748 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 08, 2023 Filed Jun 9, 2023 20:24 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	5,000	$15.74	$78,686.50	Disclosure SEC source: 0001209191-23-035849 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.1401 to $16.0950, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 08, 2023 Filed Jun 9, 2023 20:24 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035849 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,318,420 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:24 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	15,000	$16.92	$253,870.50	Disclosure SEC source: 0001209191-23-035849 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:24 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035849 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,323,420 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 06, 2023 Filed Jun 7, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	29,975	$17.02	$510,165.51	Disclosure SEC source: 0001209191-23-035068 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 to $17.10, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 06, 2023 Filed Jun 7, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	29,975	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035068 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,338,420 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 05, 2023 Filed Jun 7, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	22,434	$16.70	$374,611.91	Disclosure SEC source: 0001209191-23-035068 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 05, 2023 Filed Jun 7, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	22,434	$0.00	$0.00	Disclosure SEC source: 0001209191-23-035068 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,368,395 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 01, 2023 Filed Jun 2, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	471	$14.75	$6,948.85	Disclosure SEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 5 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.78, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 01, 2023 Filed Jun 2, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	44,752	$14.35	$642,244.90	Disclosure SEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 471 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 to $14.74, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
June 01, 2023 Filed Jun 2, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	45,223	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,390,829 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	16,633	$13.65	$227,003.86	Disclosure SEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.52 to $13.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnotes 6 and 7 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	16,633	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033697 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,436,052 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 30, 2023 Filed May 31, 2023 20:15 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	16,805	$13.70	$230,240.26	Disclosure SEC source: 0001209191-23-033107 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.505 to $13.86, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 30, 2023 Filed May 31, 2023 20:15 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	16,805	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033107 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,452,685 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 26, 2023 Filed May 31, 2023 20:15 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	12,602	$13.70	$172,603.29	Disclosure SEC source: 0001209191-23-033107 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.58 to $13.915, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 26, 2023 Filed May 31, 2023 20:15 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	12,602	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033107 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,469,490 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 25, 2023 Filed May 26, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	23,161	$13.38	$309,972.93	Disclosure SEC source: 0001209191-23-032529 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.20 to $13.65, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 25, 2023 Filed May 26, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	23,161	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032529 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,482,092 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 24, 2023 Filed May 26, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	7,900	$13.66	$107,920.32	Disclosure SEC source: 0001209191-23-032529 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 24, 2023 Filed May 26, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	7,900	$0.00	$0.00	Disclosure SEC source: 0001209191-23-032529 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,505,253 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 23, 2023 Filed May 24, 2023 21:07 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	43,939	$14.74	$647,647.68	Disclosure SEC source: 0001209191-23-031916 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.41 to $14.935, inclusive. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 23, 2023 Filed May 24, 2023 21:07 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	43,939	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031916 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,513,153 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 22, 2023 Filed May 24, 2023 21:07 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	87,922	$14.13	$1,242,091.68	Disclosure SEC source: 0001209191-23-031916 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.335, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 22, 2023 Filed May 24, 2023 21:07 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	87,922	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031916 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,557,092 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F2 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 19, 2023 Filed May 22, 2023 20:21 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	63,212	$13.88	$877,066.50	Disclosure SEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 5 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.30 to $14.03, inclusive. F6 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 19, 2023 Filed May 22, 2023 20:21 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	63,212	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 4 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,645,014 F4 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 18, 2023 Filed May 22, 2023 20:21 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	14,022	$13.06	$183,170.79	Disclosure SEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.10, inclusive. F6 · ownership.nature: The securities reported in this row were directly beneficially owned by Alphabet Holdings at the time of sale. The sole member of Alphabet Holdings is XXVI. The controlling stockholder of XXVI is Alphabet Inc. Each of XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Act) securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 18, 2023 Filed May 22, 2023 20:21 UTC	Prime Medicine, Inc. PRME · Entity 5281	OtherCommon Stock	14,022	$0.00	$0.00	Disclosure SEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,708,226 F4 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by the 2019 Partnership to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2019 Partnership's affiliate, Alphabet Holdings. The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended, and pursuant to a Rule 10b5-1 plan adopted by the 2019 Partnership on April 6, 2023. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 18, 2023 Filed May 22, 2023 20:21 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	13,076	$13.01	$170,100.45	Disclosure SEC source: 0001209191-23-031450 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,722,248 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnotes 5 and 7 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 17, 2023 Filed May 18, 2023 20:16 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	15,000	$12.77	$191,599.50	Disclosure SEC source: 0001209191-23-030621 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,735,324 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.95 to $13.075, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 16, 2023 Filed May 18, 2023 20:16 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	50,649	$12.59	$637,675.97	Disclosure SEC source: 0001209191-23-030621 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,750,324 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.465 to $12.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnote 4 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 15, 2023 Filed May 16, 2023 20:16 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	157,952	$12.74	$2,012,087.35	Disclosure SEC source: 0001209191-23-029789 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,800,973 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.60 to $12.97, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 12, 2023 Filed May 16, 2023 20:16 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	27,290	$12.72	$347,221.59	Disclosure SEC source: 0001209191-23-029789 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,958,925 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.65 to $13.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnote 4 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 11, 2023 Filed May 12, 2023 20:16 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	4,807	$13.79	$66,289.97	Disclosure SEC source: 0001209191-23-029033 · doc4.xml · nonDerivative · entry 3 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,986,215 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.00, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 11, 2023 Filed May 12, 2023 20:16 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	21,819	$12.98	$283,243.35	Disclosure SEC source: 0001209191-23-029033 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 10,991,022 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $13.49, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 10, 2023 Filed May 12, 2023 20:16 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	87,397	$14.03	$1,225,804.10	Disclosure SEC source: 0001209191-23-029033 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 11,012,841 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnotes 4 and 5 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 09, 2023 Filed May 10, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	321,238	$14.08	$4,522,613.43	Disclosure SEC source: 0001209191-23-028464 · doc4.xml · nonDerivative · entry 2 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 11,100,238 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.215, inclusive. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
May 08, 2023 Filed May 10, 2023 20:17 UTC	Prime Medicine, Inc. PRME · Entity 5281	SaleCommon Stock	100,772	$14.13	$1,423,726.97	Disclosure SEC source: 0001209191-23-028464 · doc4.xml · nonDerivative · entry 1 GV 2019 GP, L.L.C. · CIK 0001845038 · 10% owner GV 2019 GP, L.P. · CIK 0001845039 · 10% owner GV 2019, L.P. · CIK 0001845041 · 10% owner GV 2021 GP, L.L.C. · CIK 0001861206 · 10% owner GV 2021 GP, L.P. · CIK 0001861216 · 10% owner GV 2021, L.P. · CIK 0001861202 · 10% owner Alphabet Inc. · CIK 0001652044 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Indirect · By GV 2019, L.P. Disclosed balance after: 11,421,476 F1 · kind: This transaction was entered into pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 and in footnote 4 of this Form 4. F3 · ownership.nature: The securities reported in this row are directly beneficially owned by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole member of GV 2019 LLC is Alphabet Holdings LLC ("Alphabet Holdings"). The sole member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to indirectly beneficially own (as the term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the "Act")) the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	243	$32.90	$7,994.70	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 7 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,260,047 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F7 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	650	$31.99	$20,793.83	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 6 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,260,290 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 to $32.20, inclusive. F7 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	47,690	$31.12	$1,484,017.42	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 5 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2019 L.P. Disclosed balance after: 4,260,940 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.51 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F7 · ownership.nature: The securities reported in this row are directly held by GV 2019, L.P. (the "2019 Partnership"). The general partner of the 2019 Partnership is GV 2019 GP, L.P. (the "2019 GP"). The general partner of the 2019 GP is GV 2019 GP, L.L.C. ("GV 2019 LLC"). The sole managing member of GV 2019 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI. The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2019 GP, GV 2019 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2019 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	242	$32.90	$7,961.80	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 4 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 0 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	651	$31.99	$20,825.82	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 3 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 242 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.58 to $32.20, inclusive. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	SaleCommon Stock	47,690	$31.12	$1,484,017.42	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 2 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Alphabet Holdings LLC Disclosed balance after: 893 F3 · kind: This transaction was entered into pursuant to a Rule 10b5-1 plan previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.51 to $31.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 and in footnote 6 of this Form 4. F5 · ownership.nature: The securities reported in this row were directly held by Alphabet Holdings at the time of sale. As noted in footnote 2 above, XXVI is the sole member of Alphabet Holdings and Alphabet Inc. is the sole controlling stockholder of XXVI. Each of XXVI and Alphabet may be deemed to have voting and investment discretion over securities directly beneficially owned by Alphabet Holdings. Each of the aforementioned entities disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document
November 04, 2022 Filed Nov 8, 2022 17:04 UTC	Verve Therapeutics, Inc. VERV · Entity 11259	OtherCommon Stock	48,583	$0.00	$0.00	Disclosure SEC source: 0001209191-22-056122 · doc4.xml · nonDerivative · entry 1 GV 2017 GP, L.L.C. · CIK 0001733338 · Member of 10% Group GV 2017 GP, L.P. · CIK 0001733339 · Member of 10% Group GV 2017, L.P. · CIK 0001733340 · Member of 10% Group GV 2019 GP, L.L.C. · CIK 0001845038 · Member of 10% Group GV 2019 GP, L.P. · CIK 0001845039 · Member of 10% Group GV 2019, L.P. · CIK 0001845041 · Member of 10% Group Alphabet Inc. · CIK 0001652044 · Member of 10% Group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By GV 2017 L.P. Disclosed balance after: 6,108,442 F1 · kind: The reported transaction represents a pro rata in-kind distribution, for no consideration, by GV 2017, L.P. (the "2017 Partnership") to its partners, which resulted in all of the securities reported in Column 4 of this row being distributed to the direct ownership of the 2017 Partnership's affiliate, Alphabet Holdings LLC ("Alphabet Holdings"). The aforementioned distribution was made in accordance with the exemptions afforded pursuant to Rules 16a-13 and/or 16a-9 promulgated under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: The securities reported in this row are directly held by the 2017 Partnership. The general partner of the 2017 Partnership is GV 2017 GP, L.P. (the "2017 GP"). The general partner of the 2017 GP is GV 2017 GP, L.L.C. ("GV 2017 LLC"). The sole managing member of GV 2017 LLC is Alphabet Holdings. The sole managing member of Alphabet Holdings is XXVI Holdings Inc. ("XXVI"). The sole controlling stockholder of XXVI is Alphabet Inc. Each of the 2017 GP, GV 2017 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. may be deemed to have voting and investment discretion over the securities directly beneficially owned by the 2017 Partnership. Each of the aforementioned parties disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.